Get the Daily Brief
Latest Biotech News
Genomic‑method advances: ultra‑mild bisulfite sequencing and benchmarking toolkit EasyGeSe
Two methodological advances aim to expand reliable genomic assays on limited clinical material. Ultra‑mild bisulfite sequencing (UMBS) reduces DNA damage during methylation profiling, boosting...
Cellarity publishes AI framework for cell‑state medicines in Science: transcriptomics meets models
Cellarity published a Science manuscript outlining a framework that integrates multi‑omic transcriptomic datasets with AI models to discover cell‑state‑correcting therapeutics. The approach trains...
Biogen bets on innate immunity: $70M deal for Vanqua's C5aR1 program
Biogen in-licensed Vanqua Bio’s preclinical C5aR1 antagonist for $70 million up front, with up to $990 million in milestone payments and tiered royalties. The deal gives Biogen exclusive worldwide...
FDA clears nonhormonal option: elinzanetant approved for hot flashes
The FDA granted approval to elinzanetant, a nonhormonal agent shown in multi‑national trials to reduce vasomotor symptoms of menopause, including hot flashes and night sweats. Regulatory documents...
GSK’s Blenrep comeback: FDA clears a narrower U.S. label
The FDA has approved GSK’s antibody‑drug conjugate Blenrep for a limited multiple myeloma indication after the drug failed a prior confirmatory trial and was pulled in 2022. The agency cleared...
Lilly buys Adverum... one‑time gene therapy prize for wet AMD
Eli Lilly agreed to acquire cash‑strapped Adverum for an upfront cash consideration and contingent value rights tied to the success of Adverum’s phase‑3 AAV gene therapy ixo‑vec for wet...
Inhibrx posts registrational win: phase II data push BLA talk
Inhibrx reported that its monoclonal antibody ozekibart met the primary endpoint in a registrational phase II study for unresectable or metastatic chondrosarcoma, producing statistically...
Deep learning revs antibiotic discovery: two Nature Biotechnology reads
Two independent Nature Biotechnology papers detail how deep‑learning approaches accelerated antibacterial discovery. One study combined phenotypic screening with deep neural networks to prioritize...
LNP anatomy revealed: biophysics links particle shape to delivery
A multidisciplinary team at the University of Pennsylvania, Brookhaven National Laboratory and collaborators mapped lipid nanoparticle (LNP) structures and linked distinct morphologies to delivery...
Retrons retooled: metagenomes yield new retron gene editors
Researchers mined bacterial and archaeal metagenomes to identify self‑priming retrons that function as DNA donors and adapted several as programmable gene editors compatible with CRISPR systems....
Moderna’s CMV vaccine misses: pivotal failure halts program
Moderna disclosed that its mRNA‑1647 cytomegalovirus (CMV) vaccine failed to meet the primary efficacy endpoint in the Phase III CMVictory trial in seronegative females aged 16–40. The company...
Tango advances PRMT5 candidate: Phase III and $225M to push pancreatic program
Tango Therapeutics announced plans for a pivotal Phase III study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTA cooperativity in MTAP‑deleted tumors, based on...
Biogen stakes $70M on Vanqua C5aR1 antagonist — immunology push
Biogen struck an exclusive global licensing deal with Vanqua Bio, paying $70 million up front for a preclinical C5aR1 antagonist and reserving up to roughly $990 million in downstream milestones....
Lilly scoops Adverum — buys phase‑3 eye gene therapy at bargain price
Eli Lilly agreed to acquire Adverum in a deal that transfers the company’s phase‑3 intravitreal gene therapy ixo‑vec to Lilly as Adverum faced cash depletion. Lilly’s upfront is modest relative to...
FDA clears GSK’s Blenrep — U.S. return comes with limits
The U.S. Food and Drug Administration approved GSK’s antibody–drug conjugate Blenrep for a narrower set of multiple myeloma patients and regimens than the company requested. The agency’s decision...
Tango pivots PRMT5 into pivotal PDAC study — raises $225M to fund push
Tango Therapeutics unveiled encouraging phase I/II data for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma, and contemporaneously raised $225...
AI accelerates antibiotic discovery — two Nature Biotechnology reports
Two complementary papers published in Nature Biotechnology demonstrate that deep‑learning approaches can materially accelerate antibacterial discovery by prioritizing novel scaffolds from...
10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents
A consortium led by 10x Genomics, together with Roche Sequencing Solutions and Prognosys, filed federal lawsuits accusing Illumina of infringing multiple patents covering spatial‑transcriptomics...
Moderna halts CMV vaccine after Phase III miss
Moderna reported that its cytomegalovirus (CMV) mRNA vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a pivotal Phase III trial and stopped development of the program. The Phase...
Ventyx’s oral NLRP3 inhibitor shows cardiovascular biomarker gains — partnership talks begin
Ventyx Biosciences released Phase II data showing its oral NLRP3 inhibitor produced rapid and sustained reductions in hsCRP and other inflammation‑related biomarkers in patients with obesity and...